How and why does access to treatment and care differ between EU Member States, and how to address it in advocacy and policy?

Presentation at the WECAN Academy 2019:

Presenter: David Haerry, EUPATI

The following presentation held at the WECAN Academy 2019 will help you to understand:

How and why does access to treatment and care differ between EU MS – examples and inequalities
Why they shouldn’t just focus on pricing as the key access barrier. Different types of barriers to access to treatment and care – reimbursement and HTA is just one barrier out of many
How to address this in patient advocacy with policy markers, regulators, HTA bodies, clinicians
What their role and responsibility in this – and how not to fall into the trap of easy solutions in a complex problem
Why barking up the wrong tree is counterproductive – understand the barrier, define an advocacy goal, and go for it with evidence-based advocacy – instead of complaining about access issues to the wrong party
Access experiences in HIV versus Hepatitis C treatments
How to lobby for access – Swiss Hepatitis Strategy as example
How to build an effective access monitoring tool: MPE example

Resources

EUPATI toolbox: eupati.eu
WHO: euro.who.int/en/publications/abstracts/medicines-reimbursement-policies-in-europe

Get the facts together

Position papers:

0205 David Haerry – How and why does access to treatment and care differ from WECANWorkgroup